U.S. markets closed

Royalty Pharma plc (RPRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
44.02-0.11 (-0.25%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close44.13
Bid43.50 x 2200
Ask45.00 x 800
Day's Range42.82 - 44.51
52 Week Range34.80 - 54.44
Avg. Volume2,204,412
Market Cap26.725B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateAug 10, 2021 - Aug 16, 2021
Forward Dividend & Yield0.68 (1.54%)
Ex-Dividend DateMay 19, 2021
1y Target Est52.71
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
-36% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Royalty Pharma to Present at Upcoming Investor Conferences

    Royalty Pharma to Present at Upcoming Investor Conferences

    NEW YORK, June 07, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of June: Goldman Sachs Global Healthcare Conference on Wednesday, June 9 at 3:50 p.m. EDTBank of America Napa Biopharma Conference on Tuesday, June 15 at 1:30 p.m. EDT The webcasts will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/news-and-events/events. Webcasts will

  • GlobeNewswire

    Royalty Pharma Announces $2.025 Billion Strategic Funding Partnership With MorphoSys

    Royalty Pharma to provide tailored funding solution to enable MorphoSys’ acquisition of Constellation PharmaceuticalsInvestment is anchored by royalties on Janssen’s TremfyaPartnership also includes royalties on four development-stage therapies, Development Funding Bonds and an investment in MorphoSys common stockRoyalty Pharma to host conference call today, Wednesday, June 2 at 8:45am EDT NEW YORK and PLANEGG, Germany, June 02, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Morp

  • Declining Stock and Decent Financials: Is The Market Wrong About Royalty Pharma plc (NASDAQ:RPRX)?
    Simply Wall St.

    Declining Stock and Decent Financials: Is The Market Wrong About Royalty Pharma plc (NASDAQ:RPRX)?

    Royalty Pharma (NASDAQ:RPRX) has had a rough three months with its share price down 13%. However, stock prices are...